NCT06979596 2026-04-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
Clinical Trials
10 trialsNCT06997029 2026-04-07
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1 Recruiting
NCT01602380 2026-02-27
FALCON
AstraZeneca
Phase 3 Completed
NCT05933395 2026-01-20
GERTRUDE
Dartmouth-Hitchcock Medical Center
Phase 2 Recruiting
NCT04214288 2025-11-20
SERENA-2
AstraZeneca
Phase 2 Active not recruiting
NCT03363893 2025-11-12
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Carrick Therapeutics Limited
Phase 1/2 Completed
NCT04738292 2024-05-03
Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)
University of Wisconsin, Madison
Phase 2 Terminated
NCT02761694 2023-05-06
MK-4440-001
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Terminated
NCT02116803 2018-03-01
An Open Label Multi-center Extension Study to Evaluate Long-term Safety/ Tolerability of Dovitinib in Patients With Solid Tumors Who Continue to Receive Treatment With Dovitinib (TKI258) in Novartis-sponsored Single Agent Dovitinib Studies Which Fulfilled the Requirements for the Primary Objective
Novartis
Phase 2/3 Completed
NCT02530411 2015-08-21
FURVA
Velindre NHS Trust
Phase 2 Unknown